EIR from the USFDA

August 1, 2026 BSE Limited Code: 532321 1st Floor, P J Towers, Dalal Street, Mumbai-400001 National Stock Exchange of India Limited Code: Zyduslife Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai-400051 Re.: Press Release Dear Sir / Madam, Please find enclosed a copy of press release dated August 1, 2026, titled “Zydus receives EIR from the USFDA for its injectable facility with VAI classification”. The contents of the press release give full details. Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large. Thanking you, Yours faithfully, For, Zydus Lifesciences Limited Dhaval N. Soni Company Secretary and Compliance Officer Membership No. FCS7063 Encl.: As above Zydus receives EIR from the USFDA for its injectable facility with VAI classification Ahmedabad, India, August 1, 2026 We wish to inform that the company has received the Establishment Inspection Report (EIR) from the USFDA for its injectable facility located at Zydus Biotech Park, Ahmedabad, with Voluntary Action Indicated (VAI) classification. The GMP surveillance inspection was conducted from 27th April to 5th May 2026. This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.